MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
53.55
-0.68
-1.25%
After Hours: 53.55 0 0.00% 19:57 12/17 EST
OPEN
54.07
PREV CLOSE
54.23
HIGH
54.49
LOW
53.50
VOLUME
14.99M
TURNOVER
--
52 WEEK HIGH
61.00
52 WEEK LOW
42.38
MARKET CAP
109.01B
P/E (TTM)
18.08
1D
5D
1M
3M
1Y
5Y
1D
SCHD: This ETF Stinks
Seeking Alpha · 2h ago
These 2 Healthcare Stocks Just Declared Dividend Raises
The Motley Fool · 4h ago
More pharmas expected to sign drug pricing deals with Trump on Friday - report
Seeking Alpha · 8h ago
Bristol-Myers Squibb to Launch Phase 3 Trial for Schizophrenia Drug KarXT in Adolescents
TipRanks · 10h ago
Bristol-Myers Squibb Advances Clinical Trial for BMS-986523 in Oncology
TipRanks · 10h ago
Is Bristol Myers (BMY) Undervalued After Its Recent Share Price Rebound?
Simply Wall St · 23h ago
Harbour BioMed, Bristol Myers More Than $1.1 Bln Deal For Next-Gen Multi-Specific Antibodies
NASDAQ · 1d ago
Analysts Warn That These 3 Stocks Could Sink Further – 12/16/2025
TipRanks · 1d ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.